Probi and Sinopharm enter strategic partnership in China

The Swedish probiotic supplier, Probi® and Sinopharm, one of China’s largest pharmaceutical & healthcare companies enter a partnership to expand the offering of premium probiotic offerings in the Chinese market.

Sinopharm will launch three probiotic supplements within the immune health, bone health and iron absorption areas based on Probi’s scientifically proven probiotic strains.

Zhang Jian Ge, Director Pharmaceutical & Chemical Division of Sinopharm, states:

“Sinopharm continues to commit to our strong sense of social responsibility of “caring for life, attending to health”. Guided by our core value “All for health, health for all”, Sinopharm’s recent strategic partnership with Probi, especially its best-in-class R&D capability helps us contribute with positive impact to China’s consumer healthcare industry.”

And she continues:

The products have clinically documented positive effects and will be introduced under a new brand to expand Sinopharm’s existing supplement portfolio.”

Probiotics are a high-growth segment in China with a growth rate of 10.3% CAGR in the next 5 years according to Euromonitor.

Veronica Dong, Head of APAC, Probi:

“We are excited to partner with Sinopharm, who shares our vision of bringing innovative and scientifically supported products into China and the APAC region. With this partnership Probi has demonstrated its position as a leading probiotic company to capture high growth markets in the region such as China.”

“The partnership between Probi and Sinopharm is an important step in our commercial efforts in offering clinically documented probiotic products to consumers all over the world, and our expansion into China is a good step forward in establishing Probi’s position in the APAC region. In our partnership with Sinopharm we feel commitment and alignment in offering high quality products based upon research, clinical documentation and performance,”

says Tom Rönnlund, CEO at Probi.